Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately
This article was originally published in The Pink Sheet Daily
Executive Summary
The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.